EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Сhanges in Blood Pressure in Patients with Breast Cancer during Polychemotherapy with Anthracyclines

Світлана Бусел, Олена Волошина, Мар'яна Абрагамович, Ольга Кузнецова, Світлана Алієва

Lviv clinical bulletin · 09.04.2026 · (1 (53)) · 25-30

DOI: 10.25040/lkv2026.01.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lviv clinical bulletin, online erschienen am 09.04.2026. Verfasst von Світлана Бусел und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Elevated blood pressure (BP) during treatment with anthracyclines, which include doxorubicin and epirubicin, may be a factor in polychemotherapy (PCT)-related cardiotoxicity, which necessitates monitoring and adjustment of BP in these patients. The aim of the study. To investigate changes in blood pressure during treatment with anthracyclines in complex therapy with cyclophosphamide and paclitaxel in patients with breast cancer. Materials and methods. The study included and randomized 86 women diagnosed with breast cancer T2-4, N0-1, M0, who received neoadjuvant PCT with anthracyclines in combination with cyclophosphamide every 3 weeks, 4 cycles per course. After completing 12 weeks of treatment with anthracyclines, the patients received weekly paclitaxel infusions.

Results

Blood pressure monitoring during PCT showed that the subjects had a significant increase in mean systolic blood pressure after infusions in the doxorubicin group (from 123.1 + 1.8 to132.3 + 2.4 mm Hg, p< 0.001) and the epirubicin group (from122.7 + 2.7 to135.6 + 2.3 mm Hg, p = 0.002). Diastolic blood pressure in the doxorubicin group increased by an average of 4.4 mm Hg (95.0 % CI: 0.5-15.1 mm Hg) and by 3.8 mm Hg (95.0 % CI: 1.8-12.4 mm Hg) in the epirubicin group. Paclitaxel treatment procedures did not lead to a significant increase in blood pressure in patients in either group. Non-pharmacological measures did not significantly affect changes in blood pressure during PCT with anthracyclines in combination with cyclophosphamide and paclitaxel in the majority of patients.

Conclusions

Polychemotherapy with anthracyclines in combination with cyclophosphamide is accompanied by a significant increase in mean blood pressure after procedures. Paclitaxel infusions were not accompanied by significant changes in mean blood pressure during procedures.

Zitieren

APA

Бусел, С., Волошина, О., Абрагамович, М., Кузнецова, О., & Алієва, С. (2026). Сhanges in Blood Pressure in Patients with Breast Cancer during Polychemotherapy with Anthracyclines. Lviv clinical bulletin, 25-30. https://doi.org/10.25040/lkv2026.01.025

Vancouver

Бусел С, Волошина О, Абрагамович М, Кузнецова О, Алієва С. Сhanges in Blood Pressure in Patients with Breast Cancer during Polychemotherapy with Anthracyclines. Lviv clinical bulletin. 2026:25-30. doi:10.25040/lkv2026.01.025

BibTeX
@article{2026,
  author = {Бусел, Світлана and Волошина, Олена and Абрагамович, Мар'яна and Кузнецова, Ольга and Алієва, Світлана},
  title = {Сhanges in Blood Pressure in Patients with Breast Cancer during Polychemotherapy with Anthracyclines},
  journal = {Lviv clinical bulletin},
  year = {2026},
  number = {1 (53)},
  pages = {25--30},
  doi = {10.25040/lkv2026.01.025}
}
Kostenlos starten →